VITROLIFE AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 164.6 SEK | -0.39% |
|
-11.41% | -15.10% |
| Apr. 18 | Nordic Stocks Closed Down Thursday; Arjo Series B Fell Furthest | DJ |
| Apr. 18 | Transcript : Vitrolife AB, Q1 2024 Earnings Call, Apr 18, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
2024-04-25
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
165.3
SEK
Average target price
231.7
SEK
Spread / Average Target
+40.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.10% | 2.07B | |
| +1.19% | 12.82B | |
| -12.75% | 7.4B | |
| +2.70% | 5.47B | |
| -1.37% | 4.51B | |
| +3.89% | 4.42B | |
| -50.71% | 3.29B | |
| +9.29% | 2.66B | |
| -2.82% | 1.68B | |
| -14.72% | 1.66B |
- Stock Market
- Equities
- VITR Stock
- News Vitrolife AB
- Swedish Medical Device Group Vitrolife's CEO Steps Down
